Genetics

Introducing Landmark Bio™ and Appointment of Ran Zheng as CEO

Thursday, July 29, 2021 - 5:00am

Landmark Bio announced today the appointment of Ran Zheng as Chief Executive Officer.

Key Points: 
  • Landmark Bio announced today the appointment of Ran Zheng as Chief Executive Officer.
  • I am delighted that Ran has joined Landmark Bio as CEO, said Alan M. Garber, Provost of Harvard University and Chair of the Board of Landmark Bio who has been leading the initiative.
  • I am very excited to join the Landmark Bio team and collaborate with the extraordinary scientists, physicians and entrepreneurs who are at the forefront of biological innovation, said Ran Zheng, CEO of Landmark Bio.
  • Ran Zheng has the skills and experience to make our vision for Landmark Bio a reality.

Rallybio Corporation Announces Pricing of Initial Public Offering

Thursday, July 29, 2021 - 2:10am

Rallybio Corporation (Rallybio), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced the pricing of its initial public offering of 6,200,000 shares of common stock at a public offering price of $13.00 per share.

Key Points: 
  • Rallybio Corporation (Rallybio), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced the pricing of its initial public offering of 6,200,000 shares of common stock at a public offering price of $13.00 per share.
  • The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Rallybio, are expected to be approximately $80.6 million.
  • The offering is expected to close on August 2, 2021, subject to the satisfaction of customary closing conditions.
  • In addition, Rallybio has granted the underwriters a 30-day option to purchase up to an additional 930,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.

Illumina to Webcast Upcoming Investor Conference

Wednesday, July 28, 2021 - 11:30pm

Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference:

Key Points: 
  • Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference:
    UBS Genomics 2.0 and MedTech Innovations Summit on August 11, 2021
    The live webcast can be accessed under the Investor Info section of the "company" tab at www.illumina.com .
  • A replay will be posted on Illuminas website after the event and will be available for at least 30 days following.
  • Illumina is improving human health by unlocking the power of the genome.
  • Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments.

Xencor to Host Second Quarter 2021 Financial Results Webcast and Conference Call on August 4, 2021

Wednesday, July 28, 2021 - 9:01pm

Xencor management will host a webcast and conference call the same day at 4:30 p.m.

Key Points: 
  • Xencor management will host a webcast and conference call the same day at 4:30 p.m.
  • ET (1:30 p.m. PT) to discuss the financial results and provide a corporate update.
  • A live webcast of the conference call will be available under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com .
  • Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases.

FDA Clears Promega OncoMate™ MSI Dx Analysis System

Wednesday, July 28, 2021 - 6:00pm

The OncoMate MSI Dx Analysis System (OncoMate MSI), developed by Promega , has been cleared by the US Food and Drug Administration (FDA) as an IVD medical device to determine microsatellite instability (MSI) status in colorectal cancer tumors.

Key Points: 
  • The OncoMate MSI Dx Analysis System (OncoMate MSI), developed by Promega , has been cleared by the US Food and Drug Administration (FDA) as an IVD medical device to determine microsatellite instability (MSI) status in colorectal cancer tumors.
  • View the full release here: https://www.businesswire.com/news/home/20210728005823/en/
    The OncoMate MSI Dx Analysis System developed by Promega has been cleared by the US Food and Drug Administration (FDA) as an in vitro diagnostic medical device to determine microsatellite instability (MSI) status in colorectal cancer tumors.
  • Promega also intends to seek regulatory clearance for a Promega MSI IVD in China where the Promega MSI technology received innovation status and priority review by the National Medical Products Administration (NMPA).
  • To learn more about the OncoMate MSI Dx Analysis System, visit: www.promega.com/OncoMateIVD
    Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry.

Global Infertility Testing and Treatment Market (2021 to 2028) - Featuring Adorfem, Cook Medical and Cooper Surgical Among Others - ResearchAndMarkets.com

Wednesday, July 28, 2021 - 1:43pm

Additionally, technological advancements in time-lapse technology, coupled with advances in embryo biopsy and genetic screening, are generating new opportunities for the infertility testing and treatment market.

Key Points: 
  • Additionally, technological advancements in time-lapse technology, coupled with advances in embryo biopsy and genetic screening, are generating new opportunities for the infertility testing and treatment market.
  • The global infertility testing and treatment market covers North America, Asia-Pacific, Latin America, Europe, Middle East and Africa regions.
  • Globally, the Asia-Pacific is anticipated to witness the fastest growth rate in the infertility testing and treatment market over the forecast period.
  • Furthermore, the rise in healthcare awareness and availability of skilled professionals is likely to enhance the demand for these treatments, thereby augmenting the growth of the infertility testing and treatment market.

Bluebird Bio and Resilience Announce Strategic Alliance to Develop Next Generation Cell Therapies

Wednesday, July 28, 2021 - 1:00pm

National Resilience, Inc. (Resilience) and bluebird bio, Inc. (NASDAQ: BLUE), today announced a strategic alliance aimed to accelerate the early research, development and delivery of cell therapies.

Key Points: 
  • National Resilience, Inc. (Resilience) and bluebird bio, Inc. (NASDAQ: BLUE), today announced a strategic alliance aimed to accelerate the early research, development and delivery of cell therapies.
  • Resilience will continue to support vector supply for both bluebird bio and 2seventy bio, bluebirds spin-off oncology cell therapy company that is expected to launch by the end of 2021.
  • View the full release here: https://www.businesswire.com/news/home/20210728005511/en/
    The 125,000-square foot facility, located in Durham, North Carolina, is currently manufacturing lentiviral vector (LVV), a critical component for cell and gene therapies.
  • In consideration for the acquisition of the bRT facility upon the closing of the transaction, bluebird will receive $110 million from Resilience.

ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2021

Wednesday, July 28, 2021 - 1:02pm

IMMUNOPRECISE ANTIBODIES LTD. (the Company or IPA) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced financial results for the full fiscal year 2021 ended April 30, 2021.

Key Points: 
  • IMMUNOPRECISE ANTIBODIES LTD. (the Company or IPA) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced financial results for the full fiscal year 2021 ended April 30, 2021.
  • Dr. Jennifer Bath, CEO of ImmunoPrecise, stated, We are pleased with our solid fiscal year end results, with consistently strong and growing recurring revenue.
  • We continue to execute on strategy including ongoing technology innovation and accelerated discovery of internal and partnered novel antibodies.
  • Successfully demonstrated pre-clinical in vivo results for TATX-03 PolyTope Therapy, a multi-membered monoclonal antibody cocktail designed to retain efficacy against SARS-CoV-2 variants.

M6P Therapeutics Presented Data on M041, A Recombinant Enzyme Therapy, for the Treatment of Sanfilippo B Syndrome at MPS 2021

Wednesday, July 28, 2021 - 12:30pm

These data illustrate M041s potential as a recombinant enzyme therapy utilizing a recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) with improved mannose 6-phosphorylation.

Key Points: 
  • These data illustrate M041s potential as a recombinant enzyme therapy utilizing a recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) with improved mannose 6-phosphorylation.
  • There are currently no approved therapies for Sanfilippo B syndrome, also known as MPS IIIB.
  • Sanfilippo B syndrome is characterized by a defect in the NAGLU gene providing instructions for producing the enzyme alpha-N-acetylglucosaminidase.
  • M6P Therapeutics is a privately held, venture-backed biotechnology company developing the next-generation of targeted recombinant enzyme and gene therapies for lysosomal storage disorders (LSDs).

Acceleron Announces Second Quarter 2021 REBLOZYL® Net Sales

Wednesday, July 28, 2021 - 12:10pm

Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced net sales of REBLOZYL(luspatercept-aamt) as reported by its global collaborator, Bristol Myers Squibb, were approximately $128 million for the second quarter ended June 30, 2021.

Key Points: 
  • Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced net sales of REBLOZYL(luspatercept-aamt) as reported by its global collaborator, Bristol Myers Squibb, were approximately $128 million for the second quarter ended June 30, 2021.
  • Acceleron expects to report royalty revenue of approximately $25.6 million from net sales of REBLOZYL in the second quarter ended June 30, 2021.
  • This compares with approximately $22.4 million in royalty revenue from approximately $112 million of net sales of REBLOZYL for the first quarter ended March 31, 2021.
  • Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases.